- Synaptogenix Inc SNPX stock is plunging on heavy volume in reaction to the release of additional analyses of its Alzheimer's candidate bryostatin, showing that it missed primary endpoints.
- The analyses were based on the results of two clinical studies.
- Data were presented at the Alzheimer's Association International Conference (AAIC). An abstract of the analyses showed that one study suffered from baseline imbalance.
- Another study was impacted by AbbVie Inc's ABBV Namenda (memantine) blocking bryostatin efficacy, according to Synaptogenix.
- However, the pooled analyses showed that the two studies produced a highly significant statistical separation of the bryostatin group from the placebo group.
- Price Action: SNPX shares are down 19.6% at $9.73 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
